Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) SVP Yakob Liawatidewi sold 1,299 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $20.26, for a total value of $26,317.74. Following the sale, the senior vice president now owns 37,463 shares of the company’s stock, valued at approximately $759,000.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Yakob Liawatidewi also recently made the following trade(s):
- On Friday, November 9th, Yakob Liawatidewi sold 17,808 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $20.97, for a total value of $373,433.76.
Shares of NASDAQ:AMPH traded down $0.54 during mid-day trading on Monday, hitting $19.61. 167,800 shares of the company traded hands, compared to its average volume of 192,288. The stock has a market cap of $928.88 million, a price-to-earnings ratio of 51.61 and a beta of 1.38. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10. Amphastar Pharmaceuticals Inc has a 12-month low of $14.40 and a 12-month high of $21.65.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The company had revenue of $75.54 million for the quarter, compared to analysts’ expectations of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. Amphastar Pharmaceuticals’s quarterly revenue was up 30.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.07 earnings per share. As a group, equities research analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 earnings per share for the current year.
Several large investors have recently made changes to their positions in AMPH. Piedmont Investment Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $128,000. Meeder Asset Management Inc. boosted its position in Amphastar Pharmaceuticals by 259.8% in the second quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock worth $160,000 after purchasing an additional 7,572 shares during the last quarter. SG Americas Securities LLC purchased a new position in Amphastar Pharmaceuticals in the second quarter worth $161,000. Nisa Investment Advisors LLC purchased a new position in Amphastar Pharmaceuticals in the third quarter worth $221,000. Finally, Paloma Partners Management Co purchased a new position in Amphastar Pharmaceuticals in the third quarter worth $223,000. 44.12% of the stock is currently owned by institutional investors.
Several equities research analysts have recently commented on AMPH shares. BidaskClub upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 5th. Wells Fargo & Co restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday, November 9th. Needham & Company LLC decreased their price objective on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Wednesday, November 14th. Finally, Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $23.60.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Recommended Story: Bull Market
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.